Erba Diagnostics Inc (ERB) 3.04 $ERB
ERBA Diagnostics, Inc. Announces Notice of Noncompliance With NYSE MKT Continued Listing Standards
GlobeNewswire - Tue Apr 21, 4:10PM CDT
ERBA Diagnostics, Inc. (NYSE MKT:ERB) (the "Company"
, a fully integrated in vitro diagnostics company, announced today that, on April 17, 2015, the Company received a letter from NYSE MKT LLC (the "Exchange" stating that the Exchange has determined that the Company is not in compliance with Sections 134 and 1101 of the Exchange's Company Guide (the "Company Guide" due to the Company's failure to timely file its Annual Report on Form 10-K for the year ended December 31, 2014 with the Securities and Exchange Commission (the "SEC". The letter also states that the Company's failure to timely file its Annual Report on Form 10-K for the year ended December 31, 2014 is a material violation of its listing agreement with the Exchange and, therefore, pursuant to Section 1003(d) of the Company Guide, the Exchange is authorized to suspend and, unless prompt corrective action is taken, remove the Company's securities from the Exchange.
ERB: 3.04 (-0.30)
ERBA Diagnostics, Inc. Announces Delay in Filing Annual Report on Form 10-K
GlobeNewswire - Thu Apr 16, 6:00AM CDT
ERBA Diagnostics, Inc. (NYSE MKT:ERB), a fully integrated in vitro diagnostics company, announced today that it is delaying the filing of its Annual Report on Form 10-K for the year ended December 31, 2014 with the Securities and Exchange Commission (the "SEC".
ERB: 3.04 (-0.30)
My Top Health Care Equipment And Supplies Stocks For 2015
Stan Stafford - at Seeking Alpha - Fri Apr 10, 12:52PM CDT
ZMH: 117.49 (+0.12), SIRO: 93.81 (+0.60), ABMD: 69.31 (-0.40), BDX: 144.33 (-1.24), MASI: 34.96 (+0.43), IRIX: 9.81 (-0.08), ALGN: 55.94 (-0.21), CYNO: 31.52 (+0.20), GB: 54.53 (-0.02), EW: 140.87 (+0.39), ANIK: 38.68 (+0.05), ERB: 3.04 (-0.30), BABY: 41.64 (+1.71), GMED: 25.09 (-0.16), BAX: 70.38 (+0.33), STJ: 73.55 (+4.43), INGN: 36.39 (-0.04)
ERBA Diagnostics Announces Delay in Filing Annual Report on Form 10-K
GlobeNewswire - Wed Apr 01, 7:00AM CDT
ERBA Diagnostics, Inc. (NYSE MKT:ERB), a fully integrated in vitro diagnostics company, announced that it is delaying the filing of its Annual Report on Form 10-K for the year ended December 31, 2014 with the Securities and Exchange Commission (the "SEC".
ERB: 3.04 (-0.30)
ERBA Diagnostics Enters Agreement to Sell Former Facilities for $23 Million
GlobeNewswire - Thu Mar 26, 7:00AM CDT
ERBA Diagnostics, Inc. (NYSE MKT:ERB) announced that its wholly-owned subsidiary - Diamedix Corporation - has entered into a purchase and sale agreement to sell its former facilities located in Miami, Florida, for $23 million. ERBA Diagnostics intends to use the net proceeds from the sale of the property for potential facilities purchases, potential strategic acquisitions and for general working capital.
ERB: 3.04 (-0.30)
ERBA Diagnostics (ERB) Rises: Stock Adds 5.3% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 20, 8:46AM CDT
ERBA Diagnostics, Inc. (ERB) was a big mover last session, as the company saw its shares rise over 5% on the day.
ABMD: 69.31 (-0.40), ERB: 3.04 (-0.30)
Erba Diagnostics Expands U.S. Distribution Network
GlobeNewswire - Mon Jan 26, 7:10AM CST
Erba Diagnostics, Inc. (NYSE MKT:ERB), strengthened its U.S. distribution network by having entered into a new agreement with Government Scientific Source and having strengthened and expanded the scope of an agreement with an existing, nationally, prominent channel partner.
ERB: 3.04 (-0.30)
ERBA Diagnostics Attains CE Mark for HB Vario A1c Detection System and Reagents for Management of Diabetes
GlobeNewswire - Wed Jan 21, 7:00AM CST
ERBA Diagnostics, Inc. (NYSE MKT:ERB), has attained CE Mark clearance for the HB Vario A1c detection system and associated reagents. Monitoring A1c values can help healthcare providers manage complications from diabetes in patients.
ERB: 3.04 (-0.30)
ERBA Diagnostics (ERB) Jumps: Stock Moves 5.8% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 19, 7:30AM CST
ERBA Diagnostics, Inc. (ERB) was a big mover last session, as the company saw its shares rise nearly 6% on the day.
INGN: 36.39 (-0.04), ERB: 3.04 (-0.30)
ERBA Diagnostics Webcast Alert: Moves Presentation at OneMedForum to January 13, 2015
GlobeNewswire - Mon Jan 12, 1:01PM CST
ERBA Diagnostics, Inc. (NYSE MKT:ERB) is moving originally scheduled presentation at the OneMedForum to Tues, January 13, 2015 at 4:40 pm PST (7:40 pm EST).
ERB: 3.04 (-0.30)
ERBA Diagnostics to Present at OneMedForum January 12, 2015
GlobeNewswire - Mon Jan 05, 2:26PM CST
ERBA Diagnostics, Inc. (NYSE MKT:ERB) Chief Executive Officer, Mohan Gopalkrishnan, will present a business overview and update at the OneMedForum investor conference on Monday, January 12, 2015 at 2:40 pm PST (5:40 pm EST).
ERB: 3.04 (-0.30)
Insider Trading Alert - CODI, ERB And FDEF Traded By Insiders
at The Street - Thu Dec 18, 10:39AM CST
Stocks with insider trader activity include CODI, ERB and FDEF
CODI: 17.12 (-0.04), FDEF: 33.91 (+0.31), ERB: 3.04 (-0.30)
ERBA Diagnostics to Present at the LD Micro Conference December 4, 2014
GlobeNewswire - Wed Nov 26, 1:04PM CST
ERBA Diagnostics, Inc. (NYSE MKT:ERB) Chief Executive Officer, Mohan Gopalkrishnan, will present a business overview and update at the LD Micro Investor Conference Thursday, December 4, 2014 at 7:30 am PST (10:30 am EST).
ERB: 3.04 (-0.30)
ERBA Diagnostics misses by $0.01, misses on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 7:02AM CST
ERB: 3.04 (-0.30)
ERBA Diagnostics Reports 3rd Quarter Financial Results
GlobeNewswire - Mon Nov 10, 6:10AM CST
ERBA Diagnostics, Inc. (NYSE MKT:ERB), a fully integrated in vitro diagnostics company, today announced third quarter 2014 financial results.
ERB: 3.04 (-0.30)
ERBA to Feature New Urinalysis and Diabetes Monitoring Systems at MEDICA 2014
GlobeNewswire - Fri Nov 07, 9:14AM CST
ERBA Diagnostics, Inc. (NYSE MKT:ERB) will be featuring two new fully automated diagnostic testing instruments, the Hb-Vario diabetes monitoring system and the Laura XL urinalysis processer, at MEDICA 2014 in Dusseldorf Germany, November 12-15. ERBA Diagnostics will also showcase its comprehensive range of testing products, including the Elisa systems for autoimmune and infectious disease, chemistry analyzers, hematology analyzers, urine analyzers and coagulation systems.
ERB: 3.04 (-0.30)
Erba Diagnostics reports November 10
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 9:52AM CST
ERB: 3.04 (-0.30)
ERBA Diagnostics to Report Third Quarter Financial Results November 10th; Management Conference Call to Follow
GlobeNewswire - Wed Nov 05, 9:28AM CST
ERBA Diagnostics, Inc. (NYSE MKT:ERB) will report its third quarter 2014 financial results Monday, November 10, 2014 at approximately 7:30 a.m. Eastern Time. ERBA Chief Executive Officer Mohan Gopalkrishnan, will host a management conference call at 9:00 a.m. Eastern Time to discuss the financial results and business developments.
ERB: 3.04 (-0.30)
ERBA Diagnostics Enters Brazilian Market; Offers In Vitro Diagnostics to Hospitals, Testing Labs and Physicians Clinics
GlobeNewswire - Wed Oct 22, 8:43AM CDT
ERBA Diagnostics, Inc. (NYSE MKT:ERB) today announced its fully integrated portfolio of in vitro diagnostics platforms and reagents for Hematology and Clinical Chemistry are now available to hospitals, references labs and physician clinics in Brazil. ERBA Diagnostics' product line includes a comprehensive suite of instruments, reagents and kits for immunology, clinical chemistry, hematology, diabetes and infectious disease testing. ERBA Diagnostics intends to introduce its full suite of products to hospitals, references labs and physician clinics in Brazil as the product registrations in Brazil are completed.
ERB: 3.04 (-0.30)
Erba Diagnostics (ERB) Downgraded From Buy to Hold
at The Street - Fri Oct 17, 8:05AM CDT
Erba Diagnostics (ERB) has been downgraded by TheStreet Ratings from Buy to Hold with a ratings score of C+.
ERB: 3.04 (-0.30)
ERBA Diagnostics, Inc. Announces Notice of Noncompliance With NYSE MKT Continued Listing Standards
GlobeNewswire - Tue Apr 21, 4:10PM CDT
ERBA Diagnostics, Inc. (NYSE MKT:ERB) (the "Company"
, a fully integrated in vitro diagnostics company, announced today that, on April 17, 2015, the Company received a letter from NYSE MKT LLC (the "Exchange" stating that the Exchange has determined that the Company is not in compliance with Sections 134 and 1101 of the Exchange's Company Guide (the "Company Guide" due to the Company's failure to timely file its Annual Report on Form 10-K for the year ended December 31, 2014 with the Securities and Exchange Commission (the "SEC". The letter also states that the Company's failure to timely file its Annual Report on Form 10-K for the year ended December 31, 2014 is a material violation of its listing agreement with the Exchange and, therefore, pursuant to Section 1003(d) of the Company Guide, the Exchange is authorized to suspend and, unless prompt corrective action is taken, remove the Company's securities from the Exchange. ERB: 3.04 (-0.30)
ERBA Diagnostics, Inc. Announces Delay in Filing Annual Report on Form 10-K
GlobeNewswire - Thu Apr 16, 6:00AM CDT
ERBA Diagnostics, Inc. (NYSE MKT:ERB), a fully integrated in vitro diagnostics company, announced today that it is delaying the filing of its Annual Report on Form 10-K for the year ended December 31, 2014 with the Securities and Exchange Commission (the "SEC"
. ERB: 3.04 (-0.30)
My Top Health Care Equipment And Supplies Stocks For 2015
Stan Stafford - at Seeking Alpha - Fri Apr 10, 12:52PM CDT
ZMH: 117.49 (+0.12), SIRO: 93.81 (+0.60), ABMD: 69.31 (-0.40), BDX: 144.33 (-1.24), MASI: 34.96 (+0.43), IRIX: 9.81 (-0.08), ALGN: 55.94 (-0.21), CYNO: 31.52 (+0.20), GB: 54.53 (-0.02), EW: 140.87 (+0.39), ANIK: 38.68 (+0.05), ERB: 3.04 (-0.30), BABY: 41.64 (+1.71), GMED: 25.09 (-0.16), BAX: 70.38 (+0.33), STJ: 73.55 (+4.43), INGN: 36.39 (-0.04)
ERBA Diagnostics Announces Delay in Filing Annual Report on Form 10-K
GlobeNewswire - Wed Apr 01, 7:00AM CDT
ERBA Diagnostics, Inc. (NYSE MKT:ERB), a fully integrated in vitro diagnostics company, announced that it is delaying the filing of its Annual Report on Form 10-K for the year ended December 31, 2014 with the Securities and Exchange Commission (the "SEC"
. ERB: 3.04 (-0.30)
ERBA Diagnostics Enters Agreement to Sell Former Facilities for $23 Million
GlobeNewswire - Thu Mar 26, 7:00AM CDT
ERBA Diagnostics, Inc. (NYSE MKT:ERB) announced that its wholly-owned subsidiary - Diamedix Corporation - has entered into a purchase and sale agreement to sell its former facilities located in Miami, Florida, for $23 million. ERBA Diagnostics intends to use the net proceeds from the sale of the property for potential facilities purchases, potential strategic acquisitions and for general working capital.
ERB: 3.04 (-0.30)
ERBA Diagnostics (ERB) Rises: Stock Adds 5.3% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 20, 8:46AM CDT
ERBA Diagnostics, Inc. (ERB) was a big mover last session, as the company saw its shares rise over 5% on the day.
ABMD: 69.31 (-0.40), ERB: 3.04 (-0.30)
Erba Diagnostics Expands U.S. Distribution Network
GlobeNewswire - Mon Jan 26, 7:10AM CST
Erba Diagnostics, Inc. (NYSE MKT:ERB), strengthened its U.S. distribution network by having entered into a new agreement with Government Scientific Source and having strengthened and expanded the scope of an agreement with an existing, nationally, prominent channel partner.
ERB: 3.04 (-0.30)
ERBA Diagnostics Attains CE Mark for HB Vario A1c Detection System and Reagents for Management of Diabetes
GlobeNewswire - Wed Jan 21, 7:00AM CST
ERBA Diagnostics, Inc. (NYSE MKT:ERB), has attained CE Mark clearance for the HB Vario A1c detection system and associated reagents. Monitoring A1c values can help healthcare providers manage complications from diabetes in patients.
ERB: 3.04 (-0.30)
ERBA Diagnostics (ERB) Jumps: Stock Moves 5.8% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 19, 7:30AM CST
ERBA Diagnostics, Inc. (ERB) was a big mover last session, as the company saw its shares rise nearly 6% on the day.
INGN: 36.39 (-0.04), ERB: 3.04 (-0.30)
ERBA Diagnostics Webcast Alert: Moves Presentation at OneMedForum to January 13, 2015
GlobeNewswire - Mon Jan 12, 1:01PM CST
ERBA Diagnostics, Inc. (NYSE MKT:ERB) is moving originally scheduled presentation at the OneMedForum to Tues, January 13, 2015 at 4:40 pm PST (7:40 pm EST).
ERB: 3.04 (-0.30)
ERBA Diagnostics to Present at OneMedForum January 12, 2015
GlobeNewswire - Mon Jan 05, 2:26PM CST
ERBA Diagnostics, Inc. (NYSE MKT:ERB) Chief Executive Officer, Mohan Gopalkrishnan, will present a business overview and update at the OneMedForum investor conference on Monday, January 12, 2015 at 2:40 pm PST (5:40 pm EST).
ERB: 3.04 (-0.30)
Insider Trading Alert - CODI, ERB And FDEF Traded By Insiders
at The Street - Thu Dec 18, 10:39AM CST
Stocks with insider trader activity include CODI, ERB and FDEF
CODI: 17.12 (-0.04), FDEF: 33.91 (+0.31), ERB: 3.04 (-0.30)
ERBA Diagnostics to Present at the LD Micro Conference December 4, 2014
GlobeNewswire - Wed Nov 26, 1:04PM CST
ERBA Diagnostics, Inc. (NYSE MKT:ERB) Chief Executive Officer, Mohan Gopalkrishnan, will present a business overview and update at the LD Micro Investor Conference Thursday, December 4, 2014 at 7:30 am PST (10:30 am EST).
ERB: 3.04 (-0.30)
ERBA Diagnostics misses by $0.01, misses on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 7:02AM CST
ERB: 3.04 (-0.30)
ERBA Diagnostics Reports 3rd Quarter Financial Results
GlobeNewswire - Mon Nov 10, 6:10AM CST
ERBA Diagnostics, Inc. (NYSE MKT:ERB), a fully integrated in vitro diagnostics company, today announced third quarter 2014 financial results.
ERB: 3.04 (-0.30)
ERBA to Feature New Urinalysis and Diabetes Monitoring Systems at MEDICA 2014
GlobeNewswire - Fri Nov 07, 9:14AM CST
ERBA Diagnostics, Inc. (NYSE MKT:ERB) will be featuring two new fully automated diagnostic testing instruments, the Hb-Vario diabetes monitoring system and the Laura XL urinalysis processer, at MEDICA 2014 in Dusseldorf Germany, November 12-15. ERBA Diagnostics will also showcase its comprehensive range of testing products, including the Elisa systems for autoimmune and infectious disease, chemistry analyzers, hematology analyzers, urine analyzers and coagulation systems.
ERB: 3.04 (-0.30)
Erba Diagnostics reports November 10
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 9:52AM CST
ERB: 3.04 (-0.30)
ERBA Diagnostics to Report Third Quarter Financial Results November 10th; Management Conference Call to Follow
GlobeNewswire - Wed Nov 05, 9:28AM CST
ERBA Diagnostics, Inc. (NYSE MKT:ERB) will report its third quarter 2014 financial results Monday, November 10, 2014 at approximately 7:30 a.m. Eastern Time. ERBA Chief Executive Officer Mohan Gopalkrishnan, will host a management conference call at 9:00 a.m. Eastern Time to discuss the financial results and business developments.
ERB: 3.04 (-0.30)
ERBA Diagnostics Enters Brazilian Market; Offers In Vitro Diagnostics to Hospitals, Testing Labs and Physicians Clinics
GlobeNewswire - Wed Oct 22, 8:43AM CDT
ERBA Diagnostics, Inc. (NYSE MKT:ERB) today announced its fully integrated portfolio of in vitro diagnostics platforms and reagents for Hematology and Clinical Chemistry are now available to hospitals, references labs and physician clinics in Brazil. ERBA Diagnostics' product line includes a comprehensive suite of instruments, reagents and kits for immunology, clinical chemistry, hematology, diabetes and infectious disease testing. ERBA Diagnostics intends to introduce its full suite of products to hospitals, references labs and physician clinics in Brazil as the product registrations in Brazil are completed.
ERB: 3.04 (-0.30)
Erba Diagnostics (ERB) Downgraded From Buy to Hold
at The Street - Fri Oct 17, 8:05AM CDT
Erba Diagnostics (ERB) has been downgraded by TheStreet Ratings from Buy to Hold with a ratings score of C+.
ERB: 3.04 (-0.30)
